Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors
Genes · 2024
DOI: 10.3390/genes15030321 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von Francesca Cillo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, Pediatric Section, University of Naples Federico II, 80138 Naples, Italy. Hauptthemen laut MEDLINE: DiGeorge Syndrome, Heart Defects, Congenital, MicroRNAs. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Initially described as a triad of immunodeficiency, congenital heart defects and hypoparathyroidism, 22q11.2 deletion syndrome (22q11.2DS) now encompasses a great amount of abnormalities involving different systems. Approximately 85% of patients share a 3 Mb 22q11.2 region of hemizygous deletion in which 46 protein-coding genes are included. However, the hemizygosity of the genes of this region cannot fully explain the clinical phenotype and the phenotypic variability observed among patients. Additional mutations in genes located outside the deleted region, leading to “dual diagnosis”, have been described in 1% of patients. In some cases, the hemizygosity of the 22q11.2 region unmasks autosomal recessive conditions due to additional mutations on the non-deleted allele. Some of the deleted genes play a crucial role in gene expression regulation pathways, involving the whole genome. Typical miRNA expression patterns have been identified in 22q11.2DS, due to an alteration in miRNA biogenesis, affecting the expression of several target genes. Also, a methylation epi-signature in CpG islands differentiating patients from controls has been defined. Herein, we summarize the evidence on the genetic and epigenetic mechanisms implicated in the pathogenesis of the clinical manifestations of 22q11.2 DS. The review of the literature confirms the hypothesis that the 22q11.2DS phenotype results from a network of interactions between deleted protein-coding genes and altered epigenetic regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, Pediatric Section, University of Naples Federico II, 80138 Naples, Italy.
- Department of Environmental Biological and Pharmaceutical Sciences and Technologies, Università degli Studi della Campania "Luigi Vanvitelli", 81100 Caserta, Italy.
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80138 Naples, Italy.
- Laboratory of Regulatory and Functional Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.
ORCID-Profile: Francesco Cecere, Laura Pignata, Antonio De Rosa, Giuseppe Merla, Andrea Riccio
Förderung
- Italian Ministry of Health
Zitieren
APA
Cillo, F., Coppola, E., Habetswallner, F., Cecere, F., Pignata, L., Toriello, E., De Rosa, A., Grilli, L., Ammendola, A., Salerno, P., Romano, R., Cirillo, E., Merla, G., Riccio, A., Pignata, C., & Giardino, G. (2024). Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors. Genes. https://doi.org/10.3390/genes15030321
Vancouver
Cillo F, Coppola E, Habetswallner F, Cecere F, Pignata L, Toriello E, et al. Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors. Genes. 2024. doi:10.3390/genes15030321
BibTeX
@article{Cillo2024,
author = {Cillo, Francesca and Coppola, Emma and Habetswallner, Federico and Cecere, Francesco and Pignata, Laura and Toriello, Elisabetta and De Rosa, Antonio and Grilli, Laura and Ammendola, Antonio and Salerno, Paolo and Romano, Roberta and Cirillo, Emilia and Merla, Giuseppe and Riccio, Andrea and Pignata, Claudio and Giardino, Giuliana},
title = {Understanding the Variability of 22q11.2 Deletion Syndrome: The Role of Epigenetic Factors},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15030321}
}
EUVIMED